Citing the need to make further productivity gains, AstraZeneca Plc has announced plans to eliminate 7,300 jobs by the end of 2014 or about 12% of its 60,000-strong workforce. Of this number, 2,200 positions will be taken from research and development. This is the third company-wide restructuring programme since 2007 which altogether will see the loss of 28,900 jobs and yield annual savings estimated at $5.9 billion by the end of 2014.
